Inventor profile of:

Scott Bone

City:

Bend, Oregon

Country:

United States

Published Applications:

29

Last publication date:

2025-12-25

Top Assignees for applications by Scott Bone

The entities that hold a legal rights for patent applications filed by inventor Bone Scott:

Recent patent applications by Bone Scott

Scott Bone from Bend, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-12-25
US20250387380A1
Human necessities

AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF

#2 | 2025-10-23
US20250325517A1
Human necessities

ORAL DOSAGE FORMS OF ELRAGLUSIB

#3 | 2024-11-28
US20240390345A1
Human necessities

Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea

#4 | 2024-11-28
US20240390344A1
Human necessities

Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea

#5 | 2024-11-28
US20240390343A1
Human necessities

Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea

#6 | 2024-10-24
US20240350466A1
Human necessities

Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea

#7 | 2024-06-20
US20240197696A1
Human necessities

AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF

#8 | 2024-05-09
US20240148706A1
Human necessities

Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea

#9 | 2024-04-18
US20240122907A1
Human necessities

(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea

#10 | 2024-03-21
US20240091206A1
Human necessities

Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea

#11 | 2024-02-29
US20240066013A1
Human necessities

Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea

#12 | 2024-02-29
US20240066012A1
Human necessities

COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA

#13 | 2023-12-07
US20230390258A1
Human necessities

Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea

#14 | 2023-12-07
US20230390257A1
Human necessities

Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea

#15 | 2023-12-07
US20230390256A1
Human necessities

Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea

#16 | 2023-12-07
US20230390255A1
Human necessities

Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea

#17 | 2023-08-31
US20230270728A1
Human necessities

Amorphous kinase inhibitor formulations and methods of use thereof

#18 | 2023-06-29
US20230201176A1
Human necessities

Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea

#19 | 2023-06-29
US20230201175A1
Human necessities

Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea

#20 | 2022-08-25
US20220265623A1
Human necessities

AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF

#21 | 2022-08-25
US20220265622A1
Human necessities

AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF

#22 | 2022-08-18
US20220257574A1
Human necessities

Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea

#23 | 2022-02-03
US20220031677A1
Human necessities

Amorphous kinase inhibitor formulations and methods of use thereof

#24 | 2021-07-01
US20210196693A1
Human necessities

Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea

#25 | 2021-07-01
US20210196692A1
Human necessities

Amorphous kinase inhibitor formulations and methods of use thereof

#26 | 2021-05-06
US20210128564A1
Human necessities

Compositions and methods of use of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1- methylcyclohexane-1-carboxamide

#27 | 2020-07-30
US20200237767A1
Human necessities

Compositions and methods of use of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide

#28 | 2020-04-16
US20200113908A1
Human necessities

Compositions and methods of use of cis-4-[2-{[3S,4R)-3-fluorooxan-4-yl]amino}8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide

#29 | 2019-04-04
US20190099425A1
Human necessities

Compositions and methods of use of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide

InventorID:

2469778 ⎘